about
Integrative analysis of the melanoma transcriptomeImproved survival with vemurafenib in melanoma with BRAF V600E mutationData mining The Cancer Genome Atlas in the era of precision cancer medicineSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyMEK1 mutations confer resistance to MEK and B-RAF inhibition.MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.Improved overall survival in melanoma with combined dabrafenib and trametinib.Achievements and challenges of molecular targeted therapy in melanomaHLA-G in skin cancer: a wolf in sheep's clothing?Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsExpression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patientsModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistanceAldara activates TLR7-independent immune defenceNovel MITF targets identified using a two-step DNA microarray strategyHuman CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growthThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkRASopathic skin eruptions during vemurafenib therapyMelanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 201531st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneEuropean Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.The state of melanoma: challenges and opportunitiesTumor cell plasticity and angiogenesis in human melanomasIdentification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining.
P50
Q24608060-3600D403-8DBD-4FF1-AB9B-7DC5EFEBA72CQ24631953-3042E24C-B850-405C-8C79-4EDA2C8ED06DQ26786399-36E9D667-B60F-4D7A-B429-F01BD1C85D9CQ27276774-CE7A1F5F-4302-4B7C-AED7-9DB014DA75D2Q27777362-77BD9BB9-E0E8-421B-8DFE-A016F88F3BD7Q27852083-3EFFA5A0-EE2D-4D5D-9CAE-0C96FF37485CQ27853091-26069AB6-9D6E-4B36-B233-086BF175C48EQ28083501-1BD2539E-62CA-47CE-8506-5416AEB8D765Q28182155-692B4EA5-A9CB-4BAF-B6FF-EF3345376C1DQ28272162-8A8F2FD7-971A-46EF-ADCD-0AB10F45AF3BQ28276580-CBB20F09-2EAB-4EF7-8238-963F4B16ADD0Q28282963-489156A6-29D1-4587-8102-EC9C3E2346F1Q28286677-B81A53CA-DDE9-4D57-9F93-9916A6F00B9FQ28303403-09E5C7BD-6A38-4DCF-9342-97DB200F5DEDQ28307049-CF3746A7-2FB2-4E5A-941F-60D4B72D1434Q28485085-9002F96E-DF36-4345-9381-14F901BBDFA0Q28488013-100A6A07-FA98-49F0-ABAB-F1C1207A31B4Q28553228-8C742B49-8470-42FF-8E2E-B2F4E527335AQ28553703-3BC20B6D-39DF-48D2-88B3-20129D01289BQ30235003-DA1E4EAD-3809-4F8F-94AF-7C7F8AD284CAQ30276971-EEFB42C2-1F98-47F6-A240-6AA2D675D091Q31052984-FA9056FF-3A0E-4BD0-955D-E63500401526Q31112861-50836BA6-8D12-454B-AD01-3C82888ECCAF
P50
description
onderzoeker
@nl
name
Reinhard Dummer
@en
Reinhard Dummer
@es
Reinhard Dummer
@sl
type
label
Reinhard Dummer
@en
Reinhard Dummer
@es
Reinhard Dummer
@sl
prefLabel
Reinhard Dummer
@en
Reinhard Dummer
@es
Reinhard Dummer
@sl